Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 138 of 6351
-
New hope for leukemia patients: Chemo-Free treatment shows promise
Disease control Recruiting nowThis research study will add an anti-cancer drug (called inotuzumab ozogamicin also known as "InO") to treatment for participants with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Doctors leading this study hope to learn if adding InO…
Phase 2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New hope for kids with rare cancer: modified chemo shows promise
Disease control OngoingA prospective study on the efficacy of modified ALCL99 regimens in the treatment of the current Chinese pediatric and adolescent high-risk ALCL and compared with our historical data.
Phase 3 • Sponsor: Children's Cancer Group, China • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyArtificial intelligence (AI) technology is expected to assist clinical doctors in promptly identifying cancer patients at risk of developing psychological issues and to develop preemptive management plans, thereby enhancing their quality of life. Computer vision technology can di…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
New screening approach targets lung cancer in asian women who never smoked
Diagnosis OngoingThe study team propose to develop a database and biorepository of Asian female never smokers. This population is at increased risk for developing lung cancer but do not meet current lung cancer screening criteria. Study procedures will include up to 3 low-dose CT (LDCT) scans and…
Sponsor: NYU Langone Health • Aim: Diagnosis
Last updated Jul 01, 2026 00:00 UTC
-
Major CLL trial tests which drug combo works best for new patients
Disease control OngoingThe aim of this study is to compare the efficacy of continuous ibrutinib monotherapy with fixed-duration venetoclax plus obinutuzumab and fixed-duration ibrutinib plus venetoclax by measuring progression-free survival (PFS) in patients with previously untreated CLL.
Phase 3 • Sponsor: German CLL Study Group • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New therapy aims to curb youth suicide in ERs
Symptom relief OngoingSuicide is the leading cause of death due to illness among Canadian youth, claiming more lives than any medical illness, including cancer. Suicide prevention is possible, and early intervention is needed. The investigators will examine the effectiveness of a previously-piloted, E…
Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 26, 2026 17:30 UTC
-
Radioactive therapy targets tough prostate cancers in major trial
Disease control OngoingThe purpose of this study is to evaluate the efficacy and safety of \[Lu-177\]-PNT2002 in patients with metastatic castration-resistant prostate cancer who have progressed following treatment with androgen receptor axis-targeted therapy (ARAT).
Phase 3 • Sponsor: POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Simple vaccine timing could save thousands of newborns
Prevention OngoingBacillus Calmette-Guérin (BCG) vaccination is recommended at birth to protect against tuberculosis (TB) in countries with high TB burden. BCG is supplied in multidose vials with limited durability after reconstitution. In Guinea-Bissau, this has led to a practice of only opening …
Phase 4 • Sponsor: Bandim Health Project • Aim: Prevention
Last updated Jun 27, 2026 09:05 UTC
-
New hope for kidney cancer: drug duo takes on tough tumors
Disease control OngoingThis study will compare the efficacy and safety of belzutifan + lenvatinib versus cabozantinib in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that belzutifan + lenvatinib is superior to cabozantin…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Could four drugs be better than three for myeloma?
Disease control Recruiting nowThis phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzym…
Phase 3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Could stem cells slow ALS? new trial results are in
Disease control CompletedALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
Phase 3 • Sponsor: Corestemchemon, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Can a vaccine stop oral HPV in men with HIV?
Prevention OngoingThis is a randomized, double-blinded, placebo-controlled Phase III interventional trial of the nine-valent HPV vaccine (9vHPV) to prevent persistent oral HPV infection in adult men living with HIV.
Phase 3 • Sponsor: Weill Medical College of Cornell University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outsmart Hard-to-Treat lymphoma
Disease control OngoingThis study will evaluate the efficacy and safety of glofitamab in combination with gemcitabine plus oxaliplatin (Glofit-GemOx) compared with rituximab in combination with gemcitabine plus oxaliplatin (R-GemOx) in patients with R/R DLBCL.
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Can a new clotting factor offer better bleed protection for severe hemophilia?
Disease control OngoingPrimary Objective: \- To evaluate the long-term safety of BIVV001 in previously treated subjects with hemophilia A Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding episode…
Phase 3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New drug shows promise in battle against advanced cervical cancer
Disease control CompletedThis trial is being done to find out whether tisotumab vedotin works better than chemotherapy to treat cervical cancer. People in this study have cervical cancer that has spread to other parts of the body (metastatic) or has come back after being treated (recurrent). Participant…
Phase 3 • Sponsor: Seagen, a wholly owned subsidiary of Pfizer • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Could a new pill keep multiple myeloma in check after transplant?
Disease control OngoingThis is a phase II study to evaluate the efficacy and safety of different doses of iberdomide continuous therapy as maintenancetreatment after transplant.
Phase 2 • Sponsor: Stichting European Myeloma Network • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
A simple blood draw could spot prostate cancer early
Diagnosis Recruiting nowThis study is the early detection of prostate cancer by analysing circulating bloodbased biomarkers. Based on our latest developments, we primarily aim to assess the validity of CTCs (circulating tumour cells) and tumour cell products circulating in blood (DNA, exosomes) for earl…
Sponsor: University Hospital, Montpellier • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
New drug could help kids with hemophilia a bleed less
Disease control CompletedPrimary Objective: \- To evaluate the safety of BIVV001 in previously treated pediatric participants with hemophilia A. Secondary Objectives: * To evaluate the efficacy of BIVV001 as a prophylaxis treatment. * To evaluate the efficacy of BIVV001 in the treatment of bleeding ep…
Phase 3 • Sponsor: Bioverativ, a Sanofi company • Aim: Disease control
Last updated Jun 26, 2026 16:27 UTC
-
New RSV vaccine shows promise for seniors in major trial
Vaccine OngoingThe purpose of this study is to assess the safety, reactogenicity, immunogenicity and long-term persistence of immune response up to 5 years following a single dose vaccination of GSK's investigational vaccine RSVPreF3 OA, in adults aged 60 years and above. The study will also ev…
Phase 3 • Sponsor: GlaxoSmithKline • Aim: Vaccine
Last updated Jul 16, 2026 00:00 UTC
-
Can a smart chemotherapy outsmart resistant T-Cell cancers?
Disease control OngoingThis phase I/II trial studies the safety, side effects and best dose of OBI-3424 and how well it works in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Chemo…
Phase 1/2 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC